FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292483106> ?p ?o ?g. }

• W4292483106 abstract "Abstract Background Mitogen-activated protein kinase (MAPK)-activated protein kinase-2 (MK2) is activated downstream of p38 MAPK and regulates stability of mRNAs encoding inflammatory cytokines. CC-99677 is a novel, irreversible, covalent MK2 inhibitor under development for the treatment of ankylosing spondylitis (AS) and other inflammatory diseases. As part of a phase I clinical trial to assess safety and tolerability, we evaluated target engagement, pharmacokinetics, and pharmacodynamics of CC-99677. Methods The MK2 inhibitor CC-99677 was evaluated for its effect on cytokine expression in vitro in peripheral blood mononuclear cells (PBMCs) from healthy donors and patients with a definitive AS diagnosis. A novel in vitro model was developed to compare the potential for tachyphylaxis of CC-99677 and p38 inhibitors in THP-1 cells. The effect of CC-99677 on tristetraprolin (TTP) and cytokine mRNA was assessed in stimulated human monocyte-derived macrophages. In a first-in-human study, thirty-seven healthy volunteers were randomly assigned to daily oral doses of CC-99677 or placebo, and blood was collected at pre-specified time points before and after dosing. CC-99677 concentrations were assessed in the plasma, and CC-99677 binding to MK2 was evaluated in PBMCs. Ex vivo stimulation of the whole blood was conducted from participants in the first-in-human study to assess the pharmacodynamic effects. Results In vitro, CC-99677 inhibited tumor necrosis factor (TNF), interleukin (IL)-6, and IL-17 protein production in samples of monocytes and macrophages from AS patients and healthy volunteers via an mRNA-destabilization mechanism. In the in vitro model of tachyphylaxis, CC-99677 showed a differentiated pattern of sustained TNF protein inhibition compared with p38 inhibitors. CC-99677 reduced TTP phosphorylation and accelerated the decay of inflammatory cytokine mRNA in lipopolysaccharide-stimulated macrophages. Administration of CC-99677 to healthy volunteers was safe and well-tolerated, with linear pharmacokinetics and sustained reduction of ex vivo whole blood TNF, IL-6, and chemokine synthesis. Conclusions CC-99677 inhibition of MK2 is a promising approach for the treatment of inflammatory diseases and may overcome the limitations of p38 MAPK inhibition. Trial registration ClinicalTrials.gov NCT03554993 ." @default.
• W4292483106 created "2022-08-21" @default.
• W4292483106 creator A5017003687 @default.
• W4292483106 creator A5017572254 @default.
• W4292483106 creator A5027996162 @default.
• W4292483106 creator A5034487273 @default.
• W4292483106 creator A5034621627 @default.
• W4292483106 creator A5042912939 @default.
• W4292483106 creator A5045355874 @default.
• W4292483106 creator A5047548530 @default.
• W4292483106 creator A5051558775 @default.
• W4292483106 creator A5057591838 @default.
• W4292483106 creator A5069499546 @default.
• W4292483106 creator A5073579804 @default.
• W4292483106 creator A5085456274 @default.
• W4292483106 date "2022-08-18" @default.
• W4292483106 modified "2023-10-06" @default.
• W4292483106 title "CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production" @default.
• W4292483106 cites W1555014582 @default.
• W4292483106 cites W1951221803 @default.
• W4292483106 cites W1955386538 @default.
• W4292483106 cites W1977683934 @default.
• W4292483106 cites W1982123744 @default.
• W4292483106 cites W1995620440 @default.
• W4292483106 cites W2006704004 @default.
• W4292483106 cites W2039077632 @default.
• W4292483106 cites W2046872014 @default.
• W4292483106 cites W2047152276 @default.
• W4292483106 cites W2052397527 @default.
• W4292483106 cites W2053440052 @default.
• W4292483106 cites W2054421574 @default.
• W4292483106 cites W2058839898 @default.
• W4292483106 cites W2060926408 @default.
• W4292483106 cites W2077554968 @default.
• W4292483106 cites W2107551122 @default.
• W4292483106 cites W2123524671 @default.
• W4292483106 cites W2125503650 @default.
• W4292483106 cites W2127551467 @default.
• W4292483106 cites W2132049460 @default.
• W4292483106 cites W2145707418 @default.
• W4292483106 cites W2155905959 @default.
• W4292483106 cites W2157068896 @default.
• W4292483106 cites W2171567992 @default.
• W4292483106 cites W2426420900 @default.
• W4292483106 cites W2557320445 @default.
• W4292483106 cites W2565039836 @default.
• W4292483106 cites W2763325383 @default.
• W4292483106 cites W2767945940 @default.
• W4292483106 cites W2789800940 @default.
• W4292483106 cites W2806358811 @default.
• W4292483106 cites W2908728730 @default.
• W4292483106 cites W2948626161 @default.
• W4292483106 cites W2951829513 @default.
• W4292483106 cites W2969598066 @default.
• W4292483106 cites W2973376036 @default.
• W4292483106 cites W2982670109 @default.
• W4292483106 cites W3005437125 @default.
• W4292483106 cites W3009040909 @default.
• W4292483106 cites W3034765464 @default.
• W4292483106 cites W3035000906 @default.
• W4292483106 cites W3037564779 @default.
• W4292483106 cites W30751603 @default.
• W4292483106 cites W3102566107 @default.
• W4292483106 cites W3157994245 @default.
• W4292483106 cites W3170807342 @default.
• W4292483106 cites W3200699517 @default.
• W4292483106 cites W4281877807 @default.
• W4292483106 doi "https://doi.org/10.1186/s13075-022-02850-6" @default.
• W4292483106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35982464" @default.
• W4292483106 hasPublicationYear "2022" @default.
• W4292483106 type Work @default.
• W4292483106 citedByCount "7" @default.
• W4292483106 countsByYear W42924831062022 @default.
• W4292483106 countsByYear W42924831062023 @default.
• W4292483106 crossrefType "journal-article" @default.
• W4292483106 hasAuthorship W4292483106A5017003687 @default.
• W4292483106 hasAuthorship W4292483106A5017572254 @default.
• W4292483106 hasAuthorship W4292483106A5027996162 @default.
• W4292483106 hasAuthorship W4292483106A5034487273 @default.
• W4292483106 hasAuthorship W4292483106A5034621627 @default.
• W4292483106 hasAuthorship W4292483106A5042912939 @default.
• W4292483106 hasAuthorship W4292483106A5045355874 @default.
• W4292483106 hasAuthorship W4292483106A5047548530 @default.
• W4292483106 hasAuthorship W4292483106A5051558775 @default.
• W4292483106 hasAuthorship W4292483106A5057591838 @default.
• W4292483106 hasAuthorship W4292483106A5069499546 @default.
• W4292483106 hasAuthorship W4292483106A5073579804 @default.
• W4292483106 hasAuthorship W4292483106A5085456274 @default.
• W4292483106 hasBestOaLocation W42924831061 @default.
• W4292483106 hasConcept C137061746 @default.
• W4292483106 hasConcept C1621761 @default.
• W4292483106 hasConcept C164027704 @default.
• W4292483106 hasConcept C17991360 @default.
• W4292483106 hasConcept C184235292 @default.
• W4292483106 hasConcept C185592680 @default.
• W4292483106 hasConcept C202751555 @default.
• W4292483106 hasConcept C203014093 @default.
• W4292483106 hasConcept C26291073 @default.
• W4292483106 hasConcept C2776914184 @default.
• W4292483106 hasConcept C2778690821 @default.

• next